Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P1 receptor modulator in healthy subjects
- 9 March 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Xenobiotica
- Vol. 50 (8), 947-956
- https://doi.org/10.1080/00498254.2020.1736688
Abstract
Cenerimod is a sphingosine-1-phosphate 1 receptor modulator under development for treatment of systemic lupus erythematosus. This single-centre, open-label, single-dose study investigated the mass balance and excretion routes and aimed at identifying and quantifying cenerimod metabolites in plasma, urine, and faeces after oral administration of 2 mg/100 μCi (3.7 MBq) of 14C-cenerimod. Total mean cumulative recovery was 84% of the administered dose (58–100% in faeces and 4.6–12% in urine). In a 0-504 h cross-subject area under the curve plasma pool, cenerimod and two metabolites were detected accounting for 78, 6.0, and 4.9% of total radioactivity, respectively, i.e., no major metabolite was identified in plasma. Cenerimod was only detected in faeces and accounted for 17% of the radioactivity excreted in this matrix. The metabolite M32 was detected in both urine and faeces and represented 23% and 66% of radioactivity excreted in these matrices, respectively. Other metabolites of unknown structure were detected in small amounts. Overall, M32 and cenerimod accounted for 52% and 13%, respectively, of the total radioactivity recovered. Amongst the excreted metabolites, only the non-enzymatically formed M32 represented more than 25% of total drug-related material. Therefore, no pharmacokinetic drug-drug interaction studies are foreseen.Keywords
This publication has 18 references indexed in Scilit:
- Advances in oral immunomodulating therapies in relapsing multiple sclerosisThe Lancet Neurology, 2020
- First use of cenerimod, a selective S1P1receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept studyLupus Science & Medicine®, 2019
- Absorption, disposition and metabolic pathway of amiselimod (MT-1303) in healthy volunteers in a mass balance studyXenobiotica, 2018
- Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010CNS Drugs, 2018
- Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy SubjectsInternational Journal of Molecular Sciences, 2017
- Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulatorsExpert Opinion on Drug Metabolism & Toxicology, 2016
- Metabolism of a G Protein-Coupled Receptor Modulator, Including Two Major 1,2,4-Oxadiazole Ring-Opened Metabolites and a Rearranged Cysteine-Piperazine AdductDrug Metabolism and Disposition, 2012
- A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass SpectrometryDrug Metabolism and Disposition, 2011
- Biotransformation Reactions of Five-Membered Aromatic Heterocyclic RingsChemical Research in Toxicology, 2002
- Determination of mean valproic acid serum level by assay of a single pooled sampleClinical Pharmacology & Therapeutics, 1981